JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Kodu・Aktsiate loetelu・Xencor Inc

Xencor Inc

Suletud

SektorTervishoid

12.62 5.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.76

Max

12.91

Põhinäitajad
By Trading Economics
Sissetulek	92M 85M
Müük	7.2M 28M
Aktsiakasum	-0.09
Kasumimarginaal	302.738
Töötajad	260
EBITDA	1.4M 5.7M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+112.74% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	135M 961M
Eelmine avamishind	6.75
Eelmine sulgemishind	12.62

Uudiste sentiment

By Acuity

50%

175 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

7.87 / 10.84 Toetus ja vastupanu

Xencor Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. mai 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1. mai 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1. mai 2026, 18:37 UTC

Suurimad hinnamuutused turgudel

Senseonic Shares Slide on Underwritten Offering Price

1. mai 2026, 16:46 UTC

Suurimad hinnamuutused turgudel

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. mai 2026, 20:42 UTC

Tulu

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1. mai 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. mai 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1. mai 2026, 19:18 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1. mai 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1. mai 2026, 18:36 UTC

Tulu

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1. mai 2026, 18:35 UTC

Tulu

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. mai 2026, 18:28 UTC

Tulu

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1. mai 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1. mai 2026, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Barclays Completes Acquisition of Best Egg

1. mai 2026, 18:04 UTC

Tulu

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1. mai 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1. mai 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1. mai 2026, 17:30 UTC

Market Talk

Tulu

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1. mai 2026, 17:28 UTC

Market Talk

Tulu

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1. mai 2026, 17:21 UTC

Market Talk

Tulu

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1. mai 2026, 17:19 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1. mai 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1. mai 2026, 16:23 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. mai 2026, 16:15 UTC

Tulu

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1. mai 2026, 16:11 UTC

Market Talk

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1. mai 2026, 16:04 UTC

Tulu

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Xencor Inc Prognoos

Hinnasiht

By TipRanks

112.74% tõus

12 kuu keskmine prognoos

Keskmine 24.72 USD 112.74%

Kõrge 43 USD

Madal 12.74 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Xencor Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Xencor Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

7.87 / 10.84Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

175 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.